Help
Options
Didn't know it?
click below
click below
Knew it?
click below
click below
Don't Know
Remaining cards (0)
Know
retry
shuffle
restart
0:00
Embed Code - If you would like this activity on your web page, copy the script below and paste it into your web page.
Normal Size Small Size show me how
Normal Size Small Size show me how
Guidelines
USPSTF Guidelines
| Question | Answer |
|---|---|
| Breast exam/mammo: ACS vs USPSTF | ACS: all women of average risk: mammogram q yr from 40 yo; USPSTF mammo q 2 yrs from 50 yo |
| USPSTF prostate cancer screening | M <75: Insufficient evidence for/against. M>75: do not screen |
| USPSTF for AAA: repair what in who? | large AAA (> 5.5 cm) in M 65-75 w/ Hx of SMK; No gdln for men 65-75 no hx SMK; gdln against screen in women |
| USPSTF AAA Screening | All M 60-75 - onetime US screening. All F 60-85 w/ 1 or more CVD risk factor; M&F > 50 w/ FH AAA |
| DM: screening: | annual: retinopathy (dilated eye exam); urine albumin; SCr |
| Diabetes Screening: USPSTF Guidelines (2008) | No need to screen asymptomatic adults with BP ≤135/80; Should screen adults with HTN (sustained BP >135/80) |
| Thyroid screening | USPSTF: no recs; ATA: TSH screen start at 35 yo & q5 yrs (sooner if risk factors or sx) |
| Lipid screen for pts w/o CVD hx: | M annual at 35 yo; F annual at 45 yo |
| USPSTF: testicular cancer | against routine screening in Asx men |
| USPSTF: Mammography | Q1-2 years >40. Baseline at 50 yo, then biennial until 74 yo. |
| BSE recommendations | ACS: BSE is an option starting in pts' 20s. USPSTF: Grade D (no benefit) |
| Women at high risk for BrCa (greater than 20% lifetime risk) should get: | an MRI and a mammogram every year |
| Who should be tested for chlamydia | Women<26 yo annually, new sex partner in past 60 days, >2 sex partners in past year, exam findings of cervical mucopus/friability/ectopy |
| Colorectal ca (CRC) screening guidelines | Screen all pts >50 yo. Colonoscopy Q 10 yrs. FOBT + sig Q5 years. ACBE + sig Q 5 yrs |
| HIV CD4 monitoring | if CD4 >350, monitor q6 months; q3 months if otherwise or w/change in clinical status |
| needlestick from HIV pt: f/u | infxn risk = 0.3%; HCW & pt s/b tested at 6 wk, 3 mos, 6 mos |
| Cervical cancer screening | paps & no hx of CIN 2 or 3; or if combined with HPV testing. Stop at 65-70 yo if 3 neg tests & no hx for 10 yrs |
| Clinical breast exam (CBE) | At least Q3 years in pt 20-39 yo, annually after 40 yo |
| USPSTF recommendations on hormone therapy (HRT) | Recommends against routine use of combined estrogen-progesterone for prevention of chronic conditions in postmenopausal women. Recommends against routine use of unopposed estrogen in postmenopausal women who had a TAH |
Created by:
Abarnard
Popular Medical sets